Clever Leaves
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 7.8m | 12.1m | 15.4m | 17.8m | 17.4m | 30.0m |
| % growth | - | 55 % | 27 % | 16 % | (2 %) | 72 % |
| EBITDA | (35.6m) | (24.7m) | (34.7m) | (25.7m) | (12.8m) | (5.0m) |
| % EBITDA margin | (454 %) | (204 %) | (226 %) | (144 %) | (73 %) | (17 %) |
| Profit | (46.0m) | (36.7m) | (45.7m) | (66.2m) | (17.9m) | (9.9m) |
| % profit margin | (587 %) | (303 %) | (297 %) | (372 %) | (103 %) | (33 %) |
| EV / revenue | - | 41.3x | 8.8x | 0.5x | -0.1x | 0.2x |
| EV / EBITDA | - | -20.3x | -3.9x | -0.3x | 0.1x | -1.4x |
| R&D budget | 1.7m | 1.0m | 1.5m | 1.7m | 1.1m | - |
| R&D % of revenue | 22 % | 8 % | 10 % | 10 % | 7 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Series B | ||
| N/A | $6.1m | Early VC | |
| N/A | $17.9m | Debt | |
| N/A | $57.5m | Late VC | |
* | N/A | $14.0m | Series E |
| N/A | N/A | IPO | |
| N/A | $1.5m | Debt | |
$25.0m | Post IPO Equity | ||
| Total Funding | $77.6m | ||
Related Content
Recent News about Clever Leaves
EditClever Leaves is a vertically integrated cannabis company that operates across the entire medical cannabis supply chain, from cultivation to distribution. The company serves pharmaceutical and wellness clients globally, providing high-quality cannabis products that meet stringent regulatory standards. Clever Leaves operates in the medical cannabis market, leveraging its extensive expertise in regulatory compliance to successfully ship products to over 15 countries. The business model focuses on producing pharma-grade cannabis extracts and flowers, which are then sold to partners who utilize these products in their own markets. Revenue is generated through the sale of these cannabis products, which are cultivated using sustainable practices such as optimizing water usage and leveraging natural sunlight. The company is committed to sustainability and innovation, continuously adapting its product portfolio to meet evolving market needs.
Keywords: cannabis, pharma-grade, sustainability, regulatory compliance, global distribution, medical cannabis, cultivation, extracts, innovation, wellness.